- Home
- ABAT vs ALXO Comparison
ABAT vs ALXO Comparison
Compare ABAT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- ALXO
- Stock Information
- Founded
- ABAT 2011
- ALXO 2015
- Country
- ABAT United States
- ALXO United States
- Employees
- ABAT N/A
- ALXO N/A
- Industry
- ABAT Metal Mining
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ABAT Basic Materials
- ALXO Health Care
- Exchange
- ABAT Nasdaq
- ALXO Nasdaq
- Market Cap
- ABAT 71.7M
- ALXO 76.5M
- IPO Year
- ABAT N/A
- ALXO 2020
- Fundamental
- Price
- ABAT $0.98
- ALXO $1.99
- Analyst Decision
- ABAT
- ALXO Strong Buy
- Analyst Count
- ABAT 0
- ALXO 5
- Target Price
- ABAT N/A
- ALXO $13.25
- AVG Volume (30 Days)
- ABAT 586.7K
- ALXO 1.1M
- Earning Date
- ABAT 11-15-2024
- ALXO 11-07-2024
- Dividend Yield
- ABAT N/A
- ALXO N/A
- EPS Growth
- ABAT N/A
- ALXO N/A
- EPS
- ABAT N/A
- ALXO N/A
- Revenue
- ABAT $545,460.00
- ALXO N/A
- Revenue This Year
- ABAT $31,748.62
- ALXO N/A
- Revenue Next Year
- ABAT N/A
- ALXO N/A
- P/E Ratio
- ABAT N/A
- ALXO N/A
- Revenue Growth
- ABAT N/A
- ALXO N/A
- 52 Week Low
- ABAT $0.73
- ALXO $1.19
- 52 Week High
- ABAT $6.45
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- ABAT 61.18
- ALXO 60.32
- Support Level
- ABAT $0.83
- ALXO $1.40
- Resistance Level
- ABAT $1.08
- ALXO $1.88
- Average True Range (ATR)
- ABAT 0.09
- ALXO 0.19
- MACD
- ABAT 0.01
- ALXO 0.02
- Stochastic Oscillator
- ABAT 57.32
- ALXO 81.15
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.